Credit: REUTERS/DADO RUVICMarch 20 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Monday did not raise any new safety concerns about Biogen Inc's BIIB.O experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.
(Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
